TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03311633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous pinning time
Description: Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous pinning time
Description: Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
Study: NCT01758432

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Apixaban
Study: NCT01287598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: CYP 2C9 (warfarin) at Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: CYP 2C19 (omeprazole) at Cycle 1
Study: NCT02011386

Intervention type: DRUG
Intervention: Treatment
Study: NCT04819399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose
Study: NCT01184976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400
Description: Plasmid DNA delivered via IM injection with electroporation
Study: NCT04209374

Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DM HA
Study: NCT02603276

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols
Description: Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Yeast Rice
Description: Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice plus Plant sterols
Description: Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
Study: NCT04749147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black and White Printed Survey
Description: This survey will feature black and white text and graphics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Printed Survey
Description: This survey will feature red text and graphics.
Study: NCT00675831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD25 Reagent Device
Description: Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
Study: NCT03587896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Help Plus
Description: 5-session psychosocial intervention
Study: NCT04324892

Intervention type: DRUG
Intervention: Treat to target
Description: All patient will received protocolized treatment with an aim to achieve SDAI remission
Study: NCT02560727

Intervention type: DEVICE
Intervention: transendoscopic enteral tubing
Description: Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration

Intervention type: DEVICE
Intervention: colonoscope
Description: FMT via colonoscope is the most common approach.
Study: NCT00746187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm
Study: NCT00934583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Image and Mood (IaM) program
Description: A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
Study: NCT01267786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver surgery
Description: hepatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver surgery
Description: hepatectomy
Study: NCT01309789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 IV every 3 weeks (Cycles 3-8)
Study: NCT01287598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: CYP 3A4 (midazolam) at Cycle 1
Study: NCT01309789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 IV every 3 weeks (Cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 IV every 3 weeks (Cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 IV every 3 weeks (Cycles 3-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 IV every 3 weeks (Cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 IV every 3 weeks (Cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
Study: NCT01287598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: CYP2C8 (rosiglitazone) at Cycle 1
Study: NCT01879813

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phospholipid drink
Description: Participant in an intervention parallel group will consume a drink with added phospholipids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo milk drink
Description: Participant in an intervention parallel group will consume a drink without added phospholipids
Study: NCT02397590

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study: NCT01157546

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline via TAP catheters
Description: A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine via TAP catheters
Description: A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
Study: NCT02026518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Study: NCT01309789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
Study: NCT01428310

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc(TM)
Description: one dissolvable bit, one time, after a period of abstinence from smoking

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CigRx(R)
Description: one dissolvable bit, one time, after a period of abstinence from smoking
Study: NCT04643847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: 110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
Study: NCT05745766

Intervention type: OTHER
Intervention: Panoramic and lateral cephalometric radiography
Description: The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.

Intervention type: OTHER
Intervention: Cone beam computed tomography
Description: The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.

Intervention type: OTHER
Intervention: Surgery
Description: The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
Study: NCT00997854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Length of time for feed administration
Description: Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of time for feed administration
Description: Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
Study: NCT00825695

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cocoa
Description: two servings of cocoa daily for one month

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cocoa
Description: two servings of cocoa daily for one month
Study: NCT03161210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose Prolotherapy
Description: Dextrose is a solution, mixture of dextrose and water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthesia
Description: A local anaesthetic is a medication that causes reversible absence of pain sensation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is a control group
Study: NCT00625534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal inguinal hernia repair
Description: 3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open tension free inguinal hernia mesh repair
Description: Classical Lichtenstein repair. Polyester flat 14x8cm mesh
Study: NCT03550573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioInsight™ Noninvasive 3D Mapping System
Description: The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioInsight™ Noninvasive 3D Mapping System
Description: The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit.
Study: NCT02524730

Intervention type: DEVICE
Group type: OTHER
Intervention: Primary total knee replacement (Scorpio NRG CR Total Knee System)
Description: Scorpio NRG CR Total Knee System
Study: NCT01076686

Intervention type: DRUG
Intervention: Questionnaire and Physical Exam
Description: A 10-question survey and a six-item physical exam were completed.

Intervention type: DRUG
Intervention: Questionnaire and Physical Exam
Description: A 10-question survey and a six-item physical exam were completed.

Intervention type: DRUG
Intervention: Questionnaire and Physical Exam
Description: A 10-question survey and a six-item physical exam were completed.

Intervention type: DRUG
Intervention: Questionnaire and Physical Exam
Description: A 10-question survey and a six-item physical exam were completed.
Study: NCT05136300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months.
Study: NCT03485183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White/Pink Noise
Description: White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
Study: NCT02922881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis Diet (UCD)
Description: The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
Study: NCT02027181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device FreeO2 v2.0
Description: * Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device FreeO2 v2.0
Description: * Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...).
Study: NCT02737982

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
Study: NCT02026518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo of soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of soy isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo of cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo of cholecalciferol
Study: NCT01637818

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lichtenstein's operation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh Plug Repair

Intervention type: DRUG
Group type: OTHER
Intervention: Opiate
Description: Postoperative pain therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Opiate
Description: Postoperative pain therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: Postoperative pain therapy
Study: NCT03945669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary Nailing
Description: fracture fixation of the tibial shaft fracture with an intramedullary nail.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Ring fixation
Description: fracture fixation of the tibial shaft fracture with an external ring fixator.
Study: NCT01637818

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: Postoperative pain therapy

Intervention type: DRUG
Group type: OTHER
Intervention: non-steroidal anti-inflammatory drug
Description: Postoperative pain therapy

Intervention type: DRUG
Group type: OTHER
Intervention: non-steroidal anti-inflammatory drug
Description: Postoperative pain therapy
Study: NCT04280406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: azithromycin 500mg one hour before implant placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: identical placebo one hour before implant placement
Study: NCT02156804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (BMS-936558)
Study: NCT03702426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: GMCSF 1.5mcg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Tablet Norfloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Description: Tablet Norfloxacin 400 mg
Study: NCT01277471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal frequency (6 meals vs. 2 meals/day)
Description: 6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6 meals/day followed by 2 meals/day
Description: 2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
Study: NCT02514850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone Combo
Description: Injection of BioChaperone Combo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix25
Description: Injection of Humalog Mix25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Injection of Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Injection of Lantus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of saline 0.9% solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of saline 0.9% solution
Study: NCT01211080

Intervention type: DRUG
Intervention: Propranolol
Description: Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
Study: NCT00883623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
Study: NCT02439931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote psychosocial intervention
Study: NCT03306524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIPPV_VG_0_08
Description: Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIPPV_VG_0_16
Description: Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIPPV_VG_0_24
Description: Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIPPV_VG_0_32
Description: Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIPPV_VG_0_40
Description: Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV_VG_0_08
Description: Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV_VG_0_16
Description: Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV_VG_0_24
Description: Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV_VG_0_32
Description: Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV_VG_0_40
Description: Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
Study: NCT03183492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix®
Description: One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT03940794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.